US Food and Drug Administration has decided to recommend a discussion of naloxone when prescribing an opioid, stopping short of a potentially costly co-prescribing requirement that had been narrowly recommended by an advisory committee.
Opioid Labeling Instructions On Naloxone Are Compromise In Co-Prescribing Debate
US FDA says opioid and opioid use disorder treatment labels should suggest providers discuss naloxone availability with patients and caregivers and consider co-prescribing to patients at high-risk of overdose, but it does not mandate co-prescribing, the most aggressive (and costly) option that had been considered.
